All eligible studies were based on trials that had investigated the effects of SGLT2 inhibition compared with placebo in patients with type 2 diabetes and reported subgroup results for those treated with or without RAAS‐Is at baseline. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.